白细胞介素-6与2型糖尿病患者的心血管和肾脏结局:CANVAS研究的新见解
在CANVAS研究的心血管高危2型糖尿病患者中,基线IL-6几何均值为1.7 pg/mL,基线IL-6每翻倍与心血管结局风险升高14%、肾脏结局风险升高21%相关。安慰剂组6年间IL-6升高5.8%,卡格列净轻度减弱这一升高(与安慰剂的绝对百分比差异4.4%,P=0.01)。第1年IL-6较基线每降低25%与心血管和肾脏结局风险分别降低7%和14%相关。
要点
- 基线IL-6每翻倍与心血管结局风险升高14%、肾脏结局风险升高21%相关。
- 安慰剂组6年间IL-6升高5.8%,卡格列净轻度减弱其升高(绝对百分比差异4.4%)。
- 第1年IL-6较基线每降低25%与心血管、肾脏结局风险分别降低7%和14%相关。
核心结论
- 在心血管高危的2型糖尿病患者中,基线IL-6及其1年变化与心血管和肾脏结局相关。
- 降低IL-6的治疗对心血管、肾脏及安全性结局的作用仍有待检验。
研究设计与样本
- CANVAS研究为随机对照试验,将心血管高危的2型糖尿病患者随机分配至卡格列净组或安慰剂组。
- 在基线及第1、3、6年测量血浆IL-6;基线IL-6数据来自3,503名(80.2%)参与者。
- 采用多变量校正Cox比例风险回归估计IL-6与结局的关联,用重复测量混合效应模型评估卡格列净对IL-6随时间变化的影响。
主要发现
- 基线IL-6几何均值为1.7 pg/mL。
- 基线IL-6每翻倍与心血管结局风险升高14%(95%CI 4, 24)和肾脏结局风险升高21%(95%CI 1, 45)相关。
- 6年间安慰剂组IL-6升高5.8%(95%CI 3.4, 8.3)。
- 卡格列净轻度减弱IL-6升高,与安慰剂的绝对百分比差异为4.4%(95%CI 1.3, 9.9;P=0.01)。
- 第1年IL-6较基线每降低25%与心血管结局风险降低7%(95%CI 1, 22)和肾脏结局风险降低14%(95%CI 5, 22)相关。
关键数值与推荐
- 复合心血管结局为非致死性心肌梗死、非致死性卒中或心血管死亡。
- 复合肾脏结局为估算肾小球滤过率持续下降≥40%、终末期肾病或肾脏相关死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The inflammatory cytokine interleukin-6 (IL-6) is associated with cardiovascular (CV) and kidney outcomes in various populations. However, data in patients with type 2 diabetes are limited. We assessed the association of IL-6 with CV and kidney outcomes in the Canagliflozin Cardiovascular Assessment Study (CANVAS) and determined the effect of canagliflozin on IL-6. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes at high CV risk were randomly assigned to canagliflozin or placebo. Plasma IL-6 was measured at baseline and years 1, 3, and 6. The composite CV outcome was nonfatal myocardial infarction, nonfatal stroke, or CV death; the composite kidney outcome was sustained ≥40% estimated glomerular filtration rate decline, end-stage kidney disease, or kidney-related death. Multivariable-adjusted Cox proportional hazards regression was used to estimate the associations between IL-6 and the outcomes. The effect of canagliflozin on IL-6 over time was assessed with a repeated-measures mixed-effects model. RESULTS: The geometric mean IL-6 at baseline, available in 3,503 (80.2%) participants, was 1.7 pg/mL. Each doubling of baseline IL-6 was associated with 14% (95% CI 4, 24) and 21% (95% CI 1, 45) increased risk of CV and kidney outcomes, respectively. Over 6 years, IL-6 increased by 5.8% (95% CI 3.4, 8.3) in the placebo group. Canagliflozin modestly attenuated the IL-6 increase (absolute percentage difference vs. placebo 4.4% [95% CI 1.3, 9.9; P = 0.01]). At year 1, each 25% lower level of IL-6 compared with baseline was associated with 7% (95% CI 1, 22) and 14% (95% CI 5, 22) lower risks for the CV and kidney outcome, respectively. CONCLUSIONS: In patients with type 2 diabetes at high CV risk, baseline IL-6 and its 1-year change were associated with CV and kidney outcomes. The effect of IL-6-lowering therapy on CV, kidney, and safety outcomes remains to be tested.
引用
- Koshino A, Schechter M, Sen T, et al. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. Diabetes Care. 2022. PMID: 36134918. doi:10.2337/dc22-0866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。